Close Menu
    Trending
    • American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
    • Air Arabia Egypt launches Cairo to Al Ain flights soon
    • TÜV SÜD opens its International Technology & Innovation Campus in the Guangdong-Hong Kong-Macao Greater Bay Area
    • Huawei Unveils Financial AI Scaling Capabilities at Singapore FinTech Festival 2026
    • Botswana opens consultations on proposed 33 percent hike now
    • UnionPay International and Transsion Announce Global Partnership to Bring UnionPay Payments to T Wallet, Debuting in Pakistan
    • Lianlian DigiTech Launches LianLian XWorker, an AI Workforce Platform for Global Commerce
    • PM Modi meets Prince and Princess of Wales for climate talks
    Friday, November 20
    UAE TribuneUAE Tribune
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    UAE TribuneUAE Tribune
    Home » Australian team finds new way to tackle triple-negative breast cancer
    Health

    Australian team finds new way to tackle triple-negative breast cancer

    August 22, 2026
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    ADELAIDE, Australia / RankWire.AI / – Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones.

    Australian team finds new way to tackle triple-negative breast cancer
    Medical scientists analyze molecular data screens to evaluate novel targeted cancer therapies.

    Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. This subtype lacks estrogen, progesterone, and HER2 receptors, rendering conventional targeted hormone therapies ineffective. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors.

    Diagnostic Biomarker Testing May Identify Patients Most Likely to Benefit

    In pre-clinical models, scientists demonstrated that restoring miR-342 levels markedly reduced the spread of cancer cells to distant organs. Furthermore, researchers discovered that palbociclib, an existing CDK4/6 inhibitor drug currently approved for hormone receptor-positive breast cancers, significantly halted metastatic tumor growth in models exhibiting low miR-342 levels. The findings suggest measuring miR-342 levels could allow doctors to repurpose existing therapeutics to treat high-risk patients.

    Co-senior author Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology confirmed that preventing metastasis remains the primary challenge in treating aggressive breast cancers. Gregory emphasized that because palbociclib targets the overactive E2F pathway, administering the drug after cancer cells spread prevented microscopic deposits from expanding. Rather than focusing solely on shrinking primary tumors, this therapeutic approach stops microscopic secondary cancers from developing into life-threatening conditions.

    Molecular Switch miR-342 Acts as Master Regulator for Cancer Genes

    The scientific team noted that triple-negative breast cancer is biologically diverse, which has historically hindered the development of universal targeted treatments. By pinpointing a specific biological weakness shared by a distinct patient subgroup, the study opens the door to personalized treatment regimens. As Australian researchers uncover a promising new way to tackle triple-negative breast cancer, research teams are preparing to validate the findings using patient-derived models ahead of clinical trials.

    Medical oncologists and cancer research organizations across Australia welcomed the findings, noting the urgent need for expanded treatment options when primary therapies fail. The research team plans to collaborate with international clinical networks to accelerate biomarker screening protocols. Validating miR-342 testing could soon allow clinicians to select suitable candidates for targeted CDK4/6 inhibitor therapies during early intervention phases.

    Related Posts

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Ebola cases top 11,200 as Africa CDC warns of record outbreak

    November 16, 2026

    Yellow fever kills 18 across nine African nations, WHO says

    November 7, 2026

    Dengue kills 173 in October as Bangladesh toll climbs to 418

    November 2, 2026

    Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

    October 28, 2026

    Malaria kills 22 in Namibia’s Zambezi Region as cases rise

    October 26, 2026
    Latest News

    Air Arabia Egypt launches Cairo to Al Ain flights soon

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Dubai Airports expects over 70 million guests in 2026

    November 18, 2026

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Over 9 million visitors lift Tunisia tourism income 3.4%

    November 17, 2026
    © 2026 UAE Tribune | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.